Rimon Golovey

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/a64720b0-f4e9-11ed-b68f-a56b34798745.jpg

First Name

Rimon

Last Name

Golovey

NPI

1225666993

Faculty ID

17585

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

123893

Visit Type ID

2541

Is Open Scheduling

On

Michele H. Mokrzycki

https://assets.montefioreeinstein.org/profiles/images/physphoto/Mokrzycki_Michele_MD-2.jpg

First Name

Michele

Last Name

Mokrzycki

NPI

1215048822

Faculty ID

4647

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Mokrzycki&nbsp;is a graduate of&nbsp;Boston College (B.S., 1983),&nbsp;and the University of Vermont College of Medicine (M.D., 1987) and received a&nbsp;Masters&nbsp;of Science&nbsp;in Clinical Research from the Albert Einstein College of Medicine (M.S. 2000). She&nbsp;completed&nbsp;both an&nbsp;Internal&nbsp;Medicine Residency and Clinical Nephrology Fellowship at the University&nbsp;of&nbsp;Connecticut Health Science Center in Farmington, CT. &nbsp;Dr Mokrzycki has been on faculty at the Albert Einstein College of Medicine since 1992, where she is a Professor of Medicine in the Division of Nephrology. &nbsp;She is a full time clinical nephrologist at the Montefiore Medical Center, Moses Campus.</p>
<p>Dr Mokrzycki's&nbsp;research interests have focused primarily on hemodialysis vascular access related complications, specifically,&nbsp;complications associated with tunneled catheter use such as infection/bacteremia/inflammation and dysfunction/thrombosis. &nbsp;</p>
<p>She is the recipient of a grant from the AETNA Foundation to study the effect of a multidisciplinary team approach to improve outcomes associated with catheter bacteremia in hemodialysis patients. &nbsp;</p>
<p>Dr Mokrzycki&nbsp;served on the Program Committee Member for the National Kidney Foundation (NKF)&nbsp;for 2 years, and on Faculty for the Therapeutic Apheresis Academy (TAA)&nbsp;for&nbsp;5 years, which is&nbsp;held annually at the University of Virginia College of Medicine. She has been an invited speaker and/or chaired sessions&nbsp;at the American Society of Nephrology (ASN),&nbsp;National Kidney Foundation (NKF), the Vascular Access Society (VAS), Hemodialysis University (HDU), Annual Dialysis Conference (ADC), the&nbsp;American Society of Diagnostic and Interventional Nephrology (ASDIN), and the VEITH symposium.</p>
<p>Dr Mokrzycki served on the Catheter Endpoints Workgroup of the Kidney Health Initiative (KHI), formed by the American Society of Nephrology,the FDA and other stakeholders in End Stage Kidney Disease Innovation. &nbsp;Dr Mokrzycki currently serves as the Chair of the Vascular Accesss Outcomes Workgroup, a subgroup of the Nephrologists Transforming Dialysis Safety Initiative (NTDS), which is a collaboration between the American Society of Nephrology and the Centers for Disease Control.&nbsp;</p>
<p>&nbsp;</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

<p>Dr. Mokrzycki is board certified in Nephrology and is a Fellow of the American Society of Nephrology. Clinical interests include Glomerular Diseases, Acute and Chronic Kidney Diseases, Hypertension, Kidney Stones, Renal Cystic Diseases, Dialysis, and Vascular Access for Hemodialysis.</p>

Research Focus

<p>Dr. Mokrzycki completed a Masters Program in Clinical Research at the Albert Einstein College of Medicine. The author of over 50 peer-reviewed publications, Dr. Mokrzycki&rsquo;s research focuses on reducing hemodialysis vascular access infectious and thrombotic complications.</p>

Elsevier Profile

Selected Publications

<ol>
<li><strong>Mokrzycki MH</strong>, Yamase H, Kohn OF.&nbsp; Renal malacoplakia with papillary necrosis and renal failure. Am J Kidney Dis 19:587-91, 1992.</li>
<li><strong>Mokrzycki MH</strong>, Kaplan AA.&nbsp; Therapeutic Plasma Exchange: Complications and management.&nbsp; Am J Kidney Dis 23:817-27, 1994.</li>
<li><strong>Mokrzycki MH</strong>, Rickles F, Kaplan AA, Kohn OF.&nbsp; Thrombotic thrombocytopenic purpura in pregnancy: Successful treatment with plasma exchange.&nbsp; Blood Purif 13:271-82, 1995.</li>
<li>Posner L, <strong>Mokrzycki MH</strong>. Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use.&nbsp; Am J Nephrol 16:339-43,1996.</li>
<li>Kerr A, Spector J, <strong>Mokrzycki MH</strong>, Blau S, Simon R.&nbsp; V asodilator provocation of occult urinar y tract hemorrhage. J Trauma 40:152-4, 1996.</li>
<li><strong>Mokrzycki MH</strong><span style="text-decoration: underline;">,</span> Kaplan AA.&nbsp; Protein losses in continuous renal replacement therapies. J Am Soc Nephrol 7:1-5, 1996.</li>
<li><strong>Mokrzycki MH</strong><span style="text-decoration: underline;">,</span> Harris C, May H, Laut J, Palmisano J.&nbsp; Lactic acidosis associated with stavudine (d4T): Report of 5 cases. Clin Inf Dis 30:198-200, 2000.</li>
<li><strong>Mokrzycki MH</strong>, Schroppel B, von Gersdorff G, Rush H, Zdunek M, Feingold R.&nbsp; Tunneled cuffed catheter associated infections in hemodialysis patients seropositive for the human immunodeficiency virus.&nbsp; J Am Soc Nephrol 11:2122-2127, 2000.</li>
<li>Barisoni L, <strong>Mokrzycki MH</strong>, Sablay L, Nagata M, Yamase H, Mundel P.&nbsp; Podocyte cell cycle regulation and proliferation in collapsing glomerulopathies.&nbsp; Kidney Int 58:137-143, 2000.</li>
<li>Zdunek MP, Mitra A, <strong>Mokrzycki MH</strong>.&nbsp; Plasma exchange for the removal of digoxin-specific antibody fragments in renal failure: Timing is important for maximizing clearance.&nbsp; Am J Kidney Dis 36:177-183, 2000.</li>
<li>Solomon N, <strong>Mokrzycki MH</strong>.&nbsp; Levofloxacin-associated allergic interstitial nephritis.&nbsp; Clin Nephrol 54:356, 2000.</li>
<li><strong>Mokrzycki MH</strong>, Jean-Jerome K, Rush H, Zdunek MP, Rosenberg SO.&nbsp; A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters. Kidney Int 59:1935-1942, 2001.</li>
<li>Swiatecka-Urban A, <strong>Mokrzycki MH</strong>, Kaskel F, Da Silva F, Denamur E.&nbsp; Novel WT1 mutation (C388Y) in a female child with Denys-Drash syndrome.&nbsp;&nbsp; Pediatr Nephrol 16:627-630, 2001.</li>
<li><strong>Mokrzycki MH,</strong> Singhal A.&nbsp; Cost-Effectiveness of Three Strategies of Managing Tunneled-Cuffed Hemodialysis Catheters (TCC) in Clinically Mild or Asymptomatic Bacteremias.&nbsp; Nephrol Dial Transpl 17(12): 2196-203, 2002.</li>
<li>Negulescu O, Coco M, Croll J, <strong>Mokrzycki MH</strong>. Large atrial thrombus formation associated with tunneled cuffed hemodialysis catheters. Clin Nephrol 59(1):40-6, 2003.</li>
<li>Golestaneh L, Laut J, Rosenberg S, Zhang M, <strong>Mokrzycki MH</strong>.&nbsp; Favourable outcomes in episodes of Pseudomonas bacteremia when associated with tunneled cuffed catheters (TCC) in chronic hemodialysis patients.&nbsp; Nephrol Dial Transplant. May;21(5):1328-33,2006.</li>
<li><strong>Mokrzycki MH</strong>, Zhang M, Cohen H, Golestaneh L, Laut JM, Rosenberg SO.&nbsp; Tunneled Hemodialysis Catheter Bacteremia: Risk factors for bacteremia recurrence, infectious complications and mortality. Nephrol Dial Transplant. 21(4):1024-31,2006.</li>
<li><strong>Mokrzycki MH</strong>, Zhang M, Golestaneh L, Laut J, Rosenberg SO.A randomized controlled trial comparing two management models for the treatment of tunneled cuffed catheter (TCC) bacteremia: A collaborative team model versus usual physician-managed care. Am J Kidney Dis 48(4):587-95, 2006.</li>
<li>McKenzie LM, Hendrickson, SL, Briggs WA, Dart RA, Korbet SM, <strong>Mokrzycki MH</strong>, Kimmel PL, Ahuja TS, Berns JS, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Cho M, Zhou YC, Binns-Roemer E, Kirk GD, Kopp JB, Winkler CA.&nbsp; NPHS2 variation in sporadic focal segmental glomerulosclerosis. J Am Soc Nephrol 18(11): 2987-95, 2007</li>
<li><strong>Mokrzycki MH.</strong>&nbsp; Use of prophylactic topical or intraluminal antibiotics for hemodialysis catheters. Nat Clin Pract Nephrol 4(9):478-9, 2008.</li>
<li>Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, Oleksyk T, McKenzie LM, Kajiyama H, Ahuja TS, Berns JS, Briggs W, Cho ME, Dart RA, Kimmel PL, Korbet SM, Michel DM, <strong>Mokrzycki MH</strong>, Schelling JR, Simon E, Trachtman H, Vlahov D, Winkler CA. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet. 40 (10):1175-84, 2008.</li>
<li>Sachdeva M, Bitzer M, <strong>Mokrzycki MH</strong>. Vascular access type and changes in inflammatory markers in incident dialysis patients: a pilot study.&nbsp; J Vascular Access 10(3):174-179, 2009.</li>
<li>Golestaneh L, Gofran A, <strong>Mokrzycki MH</strong>, Chen JL.&nbsp; Removal of vancomycin in sustained low-efficiency dialysis (SLED): a need for better surveillance and dosing.&nbsp; Clin Neph 72 (4):286-291.</li>
<li>Okafor C, Ward DM, <strong>Mokrzycki MH,</strong> Weinstein R, Clark P, Balogun RA.&nbsp; Introduciton and overview of therapeutic apheresis.&nbsp; J Clin Apheresis, 2010.</li>
<li>Lok CE, <strong>Mokrzycki MH</strong>.&nbsp; Advances in Hemodialysis Catheter-related Infection.&nbsp; U.S. Nephrol, 2010.</li>
<li><strong>Mokrzycki MH</strong>, Lok CE. Traditional and nontraditional strategies to optimize catheter function: <em>Go with more flow.</em> Kidney Int, 2010.</li>
<li>Lok CE, <strong>Mokrzycki MH</strong>.&nbsp; Update 2010: Catheter-related Infection in Hemodialysis Patients. Kidney Int. 2010.</li>
<li>Lok CE, <strong>Mokrzycki MH</strong>.&nbsp; Prevention and management of catheter-related infection in hemodialysis patients.&nbsp; Kidney Int. 2010;79(6):587-98.</li>
<li><strong>Mokrzycki MH</strong>, Balogun RA.&nbsp; Therapeutic Apheresis: a review of complications and recommendations for prevention and management.&nbsp; J Clin Apher 2011:26(5):243-8.</li>
<li>Lee T, <strong>Mokrzycki MH</strong>, Moist L, Maya I, Vazquez M, Lok CE; North American Vascular Access Consortium. Standardized definitions for hemodialysis vascular access. Semin Dial 2011;24(5):515-24.</li>
<li>Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, Friedman D, Briggs W, Dart R, Korbet S, <strong>Mokrzycki MH</strong>, Kimmel PL, Limous S, Ahuja TS, Berns JS, Fryc J, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Vlahov D, Pollack M, Winkler CA.&nbsp; APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-Associated nephropathy. J Am Soc Nephrol 2011;22(11):2129-37.</li>
<li>Sachdeva M, Hung A, Kovalchuk O, Bitzer M, <strong>Mokrzycki MH</strong>. The initial vascular access type contributes to inflammation in incident hemodialysis patients. Int J Nephrol Volume 2012; (2012) Article ID: 917465.</li>
<li>Lee T, Lok C, Vazquez M, Moist L, Maya I, <strong>Mokrzycki M</strong>.&nbsp; Minimizing hemodialysis catheter dysfunction: An ounce of prevention.&nbsp; Int J Nephrol; Volume 2012 (2012), Article ID: 170857.</li>
<li>Golestaneh L, <strong>Mokrzycki MH</strong>. Vascular Access in Therapeutic Apheresis: Update 2013.&nbsp; J Clin Apheresis. 2013: 28(1):64-72.</li>
<li>Nica A, Lok CE, Harris J, Lee TC, <strong>Mokrzycki MH</strong>, Maya ID, Vazquez MA, Xi W, Moist LM; From the North American Vascular Access Consortium (NAVAC). Understanding Surgical Preference and Practice in Hemodialysis Vascular Access creation. Semin Dial. 2013:26(4):520-526.</li>
<li>Bhatt DL, Kandzari DE, O&rsquo;Neill WW, D&rsquo;Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL. A controlled trial of renal denervation for resistant hypertension. N. Engl. J. Med. 2014;370 (15):1393-1401.</li>
<li><strong>Mokrzycki MH</strong>, Lok CE. Optimizing central venous catheter primary prevention trials in hemodialysis patients. Am. J.Kidney Dis. 2015;66(6):939-941.</li>
<li>Gipson DS, Troost JP, Lafayette RA, Hladunewich MA, Trachtman H, Gadegbeku CA, Sedor JR, Holzman LB, Moxey-Mims MM, Perumal K, Kaskel FJ, Nelson P, Tuttle KR, Bagnasco SM, Hogan MC, Dell KM, Appel GB, Lieske JC, Ilori TO, Sethna CB, Fervenza FC, Hogan SL, Nachman PH, Rosenberg AZ, Greenbaum LA, Meyers KE, Hewitt SM, Choi MJ, Kopp JB, Zhdanova , Hodgin JB, Johnstone DB, Adler SG, Avila-Casado C, Neu AM, Hingorani SR, Lemley KV, Nast CC, Brady TM, Barisoni-Thomas L, Fornoni A, Jennette JC, Cattran DC, Palmer MB, Gibson KL, Reich HN, <strong>Mokrzycki MH</strong>, Sambandam KK, Zilleruelo GE, Licht C, Sampson MG, Song P, Mariani LH, Kretzler M. Complete remission in the nephrotic syndrome study network. Clin J Am Soc Nephrol. 2016;11 (1):81-89.</li>
<li>Johns, TS, <strong>Mokrzycki MH</strong>. Optimal approach for the diagnosis of hemodialysis catheter-related bacteremia. Clin J Am Soc Nephrol 2016; 11.</li>
<li>Liang E, Rodriguez M, Mueller M, Abramowitz MK, <strong>Mokrzycki&nbsp; MH</strong>. Outcomes Associated with a Heparin-Free Hemodialysis Protocol and Review of the Literature. J. Clin. Nephrol. Renal Care. 2016, 2(1): 10-16.</li>
<li>Allon M, Brouwer-Maier DJ, Abreo K, Baskin KM, Bregel K, Chand D,&nbsp; Easom A, Mermel L, <strong>Mokrzycki MH</strong>, Patel PR, Roy-Chaudhury P, Shenoy S, Valentini RP, Wasse H.&nbsp; Moving Points in Nephrology: Recommended Clinical Trial Endpoints for Hemodialysis Catheters. Clin J Am Soc Nephrol. 2017</li>
<li>&nbsp;Golestaneh L, <strong>Mokrzycki MH</strong>. Prevention of Hemodialysis Catheters Infections: Ointments, Dressings, Locks and Catheter Hub Devices. Hemodial Int. Nov 2018</li>
<li>Der E, Suryawanshi H, Morozov P, Kustagi M, Goilav B, Ranabathou S, Izmirly P, Clancy R, Belmont HM, Koenigsberg M, <strong>Mokrzycki M</strong>, Rominieki H, Graham JA, Rocca JP, Bornkamp N, Jordan N, Schulte E, Wu M, Pullman J, Slowikowski K, Raychaudhuri S, Guthridge J, James J, Buyon J, Tuschl T, Putterman C; Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Consortium. Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Nat Immunol. 2019 Jul;20(7):915-927</li>
<li>Fisher M, Golestaneh L, Allon M, <span style="font-family: 'Times New Roman', serif; font-size: 12pt;">&nbsp;</span><span style="font-family: 'Times New Roman', serif; font-size: 12pt;">Abreo K, </span><strong style="font-family: 'Times New Roman', serif; font-size: 12pt;">Mokrzycki MH.&nbsp;</strong>Preventing Central Vein Catheter Associated Bloodstream Infections in Hemodialysis: Review of Current Evidence-Based Strategies and Novel Therapies. <span style="font-size: 12pt; font-family: 'Times New Roman', serif;">Clin J Am Soc Nephrol 2020;15:132-151</span></li>
<li><span style="font-size: 12.0pt; font-family: 'Times New Roman','serif'; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;">Vachharajani T , Wong L, Niyyar VD, Abreo KD, <strong>Mokrzycki MH</strong>, for the Vascular Access Workgroup of the Nephrologists Transforming Dialysis Safety Initiative of the American Society of Nephrology. Buttonhole cannulation of arteriovenous fistulas in the United States. Kidney360. 2020 </span></li>
<li><strong style="text-indent: -0.25in; font-family: 'Times New Roman', serif; font-size: 12pt;"><span style="font-size: 12pt;">Mokrzycki MH</span></strong><span style="text-indent: -0.25in; font-size: 12pt; font-family: 'Times New Roman', serif;"> and Coco M. Management of hemodialysis patients with suspected or confirmed COVID-19 infection: perspective of two nephrologists in the United States. Kidney360. 2020:1(4);273-278.</span></li>
<li><span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';">&nbsp;</span><span style="text-indent: -0.25in; font-size: 12pt; font-family: 'Times New Roman', serif;">Fisher M, Yunes M, <strong>Mokrzycki MH</strong>, Golestaneh L, Alahiri E, Coco M. &ldquo;Chronic Hemodialysis Patients Hospitalized with COVID-19 &ndash; Short-term Outcomes in Bronx, New York&rdquo;. Kidney360 June 2020</span>1.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></li>
<li><strong style="text-indent: -0.25in;"><span style="font-size: 12.0pt; font-family: 'Times New Roman',serif;">Mokrzycki MH</span></strong><span style="text-indent: -0.25in; font-size: 12pt; font-family: 'Times New Roman', serif;">, Leigh KA, Kliger AS, Niyyar VD, Bren Asp V, Golestaneh L, Taylor Q, Novosad SA. Implementation of an Electronic Catheter Checklist in Outpatient Hemodialysis Facilities: Results of a Pilot Quality Improvement Project. Kidney360&nbsp; April 2021, 2(4) 684-694</span>
<p class="MsoListParagraph" style="text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;">&nbsp;</p>
</li>
</ol>
<p><em><strong><span style="text-indent: -0.25in; font-size: 12pt; font-family: 'Times New Roman', serif;">Book Chapter</span></strong></em></p>
<p class="MsoListParagraph" style="text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 12.0pt; mso-bidi-font-size: 10.0pt; font-family: 'Times New Roman',serif;"><span style="mso-list: Ignore;">1.<span style="font: 7.0pt 'Times New Roman';">&nbsp; &nbsp; &nbsp;</span></span></span><span style="font-size: 12.0pt; mso-bidi-font-size: 10.0pt; font-family: 'Times New Roman',serif;">Fisher M, <strong style="mso-bidi-font-weight: normal;">Mokrzycki MH.</strong> Infectious complications in vascular access. Handbook of Dialysis. Nissenson: Handbook of Dialysis Therapy, 6e.</span> <span style="font-size: 12.0pt; mso-bidi-font-size: 10.0pt; font-family: 'Times New Roman',serif;">Elsevir (In press, 2021)</span></p>

EMR ID

3774

Biography

<p>Michele H. Mokrzycki, MD, MS, is an attending nephrologist and Professor, Medicine at Montefiore Einstein. Dr. Mokrzycki&rsquo;s clinical interests include glomerular diseases, acute and chronic kidney diseases, hypertension, kidney stones, renal cystic diseases, dialysis and vascular access for hemodialysis.</p><p>After earning her Bachelor of Science from Boston College in 1983, Dr. Morkrzycki pursued her Doctor of Medicine at University of Vermont College of Medicine, earning the degree in 1987. She performed her postdoctoral training at University of Connecticut Health Center, completing her residency in internal medicine in 1990 and her fellowship in clinical nephrology in 1992. Dr. Mokrzycki later pursued additional education, completing her Master of Science in clinical research at Einstein in 2000.</p><p>Author of over 50 peer-reviewed publications, Dr. Mokrzycki&rsquo;s research focuses on reducing hemodialysis vascular access infectious and thrombotic complications. She is on the editorial board for <em>Kidney360</em>, and is an invited reviewer for several publications including the <em>Journal of the American Society of Nephrology, Hemodialysis International</em> and the <em>Journal of Vascular Access.</em></p><p>Dr. Mokrzycki is board certified in Nephrology. She is a Fellow of the American Society of Nephrology and a member of several professional societies including the National Kidney Foundation, New York Society of Nephrology and the North American Vascular Access Consortium. In 2020, she was recognized as Reviewer of the Year by <em>Kidney360</em>.</p>

Is Open Scheduling

On

David M. Loeb

https://assets.montefioreeinstein.org/profiles/images/Loeb_David_MD_2x.jpg

First Name

David

Last Name

Loeb

NPI

1841236676

Faculty ID

15556

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Loeb has an active translational research laboratory focused on understanding bone tumor metastasis.&nbsp; His laboratory developed a clinically relevant mouse model of sarcoma metastasis, and has used this model to perform preclinical testing of novel agents that can interfere with this process.&nbsp; More basic scientific studies in the lab involve exploring the role of the Wnt signaling pathway in Ewing sarcoma migration, invasion, and metastasis.&nbsp; Dr. Loeb is also studying the role of an enzyme called RNA helicase DDX3 in Ewing sarcoma biology, especially how this enzyme affects the repair of damaged DNA. More recently, the laboratory has developed an interest in targeting the metabolic reprogramming associated with metastasis as a way to prevent the outgrowth of distant metastases from disseminated tumor cells.</p>
<p>&nbsp;</p>
<p>Dr. Loeb is also actively involved in clinical research, including the development of radiopharmaceutical agents for the treatment of bone metastases and the development of a small molecule inhibitor of DDX3.&nbsp; He serves as the local PI for a clinical trial of reduced intensity haploidentical bone marrow transplantation for children with high risk solid tumors.&nbsp; Finally, as an offshoot of his laboratory work, Dr. Loeb is involved in the development of biomarkers of metastatic risk and of minimal residual disease in children, adolescents, and young adults with sarcomas.</p>

Research Areas

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Loeb is a leading pediatric oncologist and NIH-funded researcher. He has extensive expertise in sarcoma research and clinical care and is a bone marrow transplantation specialist. Dr. Loeb’s research spans the spectrum from basic and translational studies to clinical trials using novel therapies.</p>

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Elsevier Profile

Selected Publications

<p>Dr. Loeb's PubMed bibliography can be found here: &nbsp;</p>
<p><a href="https://www.ncbi.nlm.nih.gov/sites/myncbi/1fiIspwqfwUE46/bibliography/5…;

EMR ID

6405

Biography

<p>David Loeb, MD, PhD, is Chief, Pediatric Hematology, Oncology and Cellular Therapy at Children&rsquo;s Hospital at Montefiore and Professor, Pediatrics and Professor, Developmental and Molecular Biology at Montefiore Einstein. His clinical work focuses on tumors of connective tissue, such as bone and muscle. He also has expertise in the care of children with other solid tumors. As a member of the bone marrow transplantation team, Dr. Loeb also cares for patients with acute leukemias and has expertise in the application of immunotherapy to childhood cancer.</p><p>Dr. Loeb earned his Bachelor of Arts in biology in 1987 at Johns Hopkins University. In 1993, he received his Doctor of Philosophy in Pathology and, in 1994, his Doctor of Medicine at Columbia University. In 1994, he also began an internship in Pediatrics at the Johns Hopkins University School of Medicine, followed by a residency in 1995 and a fellowship in Pediatric Hematology Oncology at the same institution.</p><p>Dr. Loeb has an active translational research laboratory focused on understanding bone tumor metastasis. His laboratory developed a clinically relevant mouse model of sarcoma metastasis and has used this model to perform preclinical testing of novel agents that can interfere with this process. One area of focus is the metabolic differences between cancer cells and normal cells, and between metastases and the primary tumor, with the intention of targeting these differences therapeutically. More basic scientific studies in the lab involve exploring the role of the Wnt signaling pathway in Ewing sarcoma and osteosarcoma migration, invasion and metastasis. Dr. Loeb also studies the role of an enzyme called RNA helicase DDX3 in Ewing sarcoma biology, especially how this enzyme affects the repair of damaged DNA.</p><p>Dr. Loeb is also actively involved in clinical research, including the development of radiopharmaceutical agents for the treatment of bone metastases and the development of a small molecule inhibitor of DDX3. He has also directed a clinical trial of reduced intensity haploidentical bone marrow transplantation for children with high risk solid tumors. Stemming from his laboratory work, Dr. Loeb is involved in the development of biomarkers of metastatic risk and of minimal residual disease in children, adolescents and young adults with sarcomas. Dr. Loeb&rsquo;s original research, based on his clinical and laboratory studies, has been published in multiple journals and books.</p><p>Dr. Loeb has been a recipient of many awards, including the Director&rsquo;s Teaching Award in Clinical Science from Sidney Kimmel Comprehensive Cancer Center in 2006, 2010 and 2015, and The Justin Straus Chordoma Research Award in 2009.</p>

Is Open Scheduling

Off

Anna Y. Zolotnitskaya

https://assets.montefioreeinstein.org/profiles/images/Zolotnitskaya_Anna_MD_2x_0.jpg

First Name

Anna

Last Name

Zolotnitskaya

NPI

1316949100

Faculty ID

1899

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Elsevier Profile

EMR ID

31006

Biography

<p>Anna Zolotnitskaya, MD, is Medical Director, Pediatric Dialysis at the Children&rsquo;s Hospital at Montefiore Einstein and Assistant Professor, Pediatrics at our Albert Einstein College of Medicine. Dr. Zolotnitskaya&rsquo;s clinical focus is on pediatric dialysis and pediatric renal transplantation. She leads a multidisciplinary dialysis team that provides patient-centered, evidence-based care for children and young adults with end-stage kidney disease. </p><p>After obtaining her Doctor of Medicine at St. Petersburg Pediatric Academy in St. Petersburg, Russia, in 1983, Dr. Zolotnitskaya completed her pediatrics internship at the same institution in 1984. She remained there to complete her pediatrics residency in 1989, before completing an additional pediatrics residency at Soroka Medical Center in Beer-Sheva, Israel, in 1994. Following this, Dr. Zolotnitskaya completed a pediatric nephrology fellowship at Montefiore Einstein in 1998, followed by an additional pediatrics residency at Columbia University College of Physicians and Surgeons, St. Luke&rsquo;s-Roosevelt Hospital in 2001. </p><p>Dr. Zolotnitskaya has been principal investigator and co-investigator in clinical trials that investigate medications employed for the care of children with advanced chronic kidney disease. Her work has been published in numerous peer-reviewed journals and abstracts, and she has given several invited presentations. She is also a reviewer for the <em>Journal of Pediatrics: Clinical Practice</em>. </p><p>Dr. Zolotnitskaya is board certified by the American Board of Pediatric Nephrology, the American Board of Pediatrics and the Israeli Board of Pediatrics. She is a member of the American Academy of Pediatrics, the American Society of Nephrology and the American Society of Pediatric Nephrology.

</p>

Is Open Scheduling

Off

Shiu M. Young

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Shiu

Last Name

Young

NPI

1467742726

Faculty ID

14110

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5826

Is Open Scheduling

Off

Michael Yee

https://assets.montefioreeinstein.org/profiles/images/13771-michael-yee.jpg

First Name

Michael

Last Name

Yee

NPI

1699971085

Faculty ID

13771

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5456

Is Open Scheduling

Off

Danny Woo

https://assets.montefioreeinstein.org/profiles/images/physphoto/Woo_Danny_MD_420x504.jpg

First Name

Danny

Last Name

Woo

NPI

1639272057

Faculty ID

3618

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

3880

Is Open Scheduling

Off

Lucia R. Wolgast

https://assets.montefioreeinstein.org/profiles/images/Wolgast_Lucia_MD_2x.jpg

First Name

Lucia

Last Name

Wolgast

NPI

1770881260

Faculty ID

12874

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Hematology and Coagulation<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Antiphospholipid Syndrome<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

4811

Is Open Scheduling

Off

Samson Wiseman

https://assets.montefioreeinstein.org/profiles/images/physphoto/Wiseman_Samson_MD_420x504.jpg

First Name

Samson

Last Name

Wiseman

NPI

1588761316

Faculty ID

10181

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

4748

Is Open Scheduling

Off

Daniel A. Weiser

https://assets.montefioreeinstein.org/profiles/images/Weiser_Daniel_MD_2x.jpg

First Name

Daniel

Last Name

Weiser

NPI

1225239700

Faculty ID

13846

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><span style="text-decoration: underline;"><strong>Childhood cancer research laboratory</strong></span></p>
<p>Our laboratory is focused on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. In such patients with typically incurable cancer, we are striving to identify new approaches to and types of treatment. We have multiple ongoing projects:</p>
<p><strong>+ Identification of biologic drivers of ultra-high-risk neuroblastoma</strong>. Neuroblastoma is one of the most common and deadly childhood cancers. Despite intensive research, there are limited therapeutic strategies for patients with <em>de novo </em>chemotherapy resistance that leads to particularly poor outcomes. We have been studying neuroblastoma since 2009 and are identifying additional biologic drivers of highly lethal tumors.</p>
<p>We compare tumor features from patients with early death from tumor progression compared to those with a maintained complete response. We assess unique histo-morphologic and proteomic features and computationally integrate these data with genomic and transcriptomic datasets to develop a combined predictor of primary refractory disease. Patients with this entity require non-standard and/or intensified treatment. Oncogenic drivers are being characterized in the lab which will facilitate strategies for novel pharmacologic intervention.</p>
<p><strong>+ Characterization of neuroblastoma development from neural crest cells</strong>.&nbsp; We are studying pathways and interactions that results in uncontrolled cell proliferation early in neuroblastoma development with an ultimate goal of identifying new targets and approaches for pharmacologic intervention.</p>
<p><strong>+ Evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma</strong>.&nbsp; With expected outcomes lagging behind those of more common childhood cancers, children with neuroblastoma require new approaches to treatment. Our lab works with multiple international clinical and research consortium groups to perform preclinical studies that substantiate human clinical trials.&nbsp;</p>
<p><strong>+ Detection of circulating tumor DNA in osteosarcoma</strong>. With no reliable non-invasive approach for disease monitoring during and after treatment, we are applying cutting edge next-generation sequencing approaches to identify solid tumors with a blood-based &ldquo;liquid&rdquo; biopsies. This will allow clinicians to assess tumor responsiveness to chemotherapy and predict likelihood of recurrence.</p>
<p><strong>+ Assessment of accelerated aging using miRNA-seq in survivors of childhood cancer</strong>. Chemotherapy has many untoward effects on healthy cells and leads to many signs of accelerated aging in children treated for cancer. Using a known microRNA &ldquo;aging&rdquo; signature discovered at Albert Einstein College of Medicine, we are studying what causes this phenotype in childhood cancer, with a goal of offering improved intervention to minimize long-term toxicity of treatment.</p>
<p><strong><span style="text-decoration: underline;">Physician Summary</span></strong></p>
<p>Daniel A. Weiser, MD, is board-certified in pediatric hematology/oncology with clinical expertise in neuroblastoma and other tumors of the adrenal glands, kidneys, liver, and gonads. He is the medical director of the intra-abdominal solid tumor program at the Children&rsquo;s Hospital at Montefiore and brings together a highly specialized multi-disciplinary care team to provide comprehensive treatment for diverse pediatric malignancies. In addition, Dr. Weiser directs a childhood cancer research laboratory that focuses on the identification of new targeted agents for cancer therapy, especially in the treatment of rare and aggressive malignancies such as neuroblastoma. His research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise for improving management of all patients with solid tumors.</p>
<p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children&rsquo;s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), Advances in Neuroblastoma Research Association (ANRA), National Pediatric Cancer Foundation (NPCF), and the American Academy of Pediatrics (AAP). He has received numerous awards including the Brigid Leventhal Special Merit Award from ASCO and the Conquer Cancer Foundation, and a prestigious K12 from the National Cancer Institute for the training of the next generation of physician-scientists in pediatric cancer. Dr. Weiser is actively involved in teaching and mentorship of trainees, and takes great pride in providing advanced and compassionate care to his patients and their families.</p>
<p><strong>Clinical Expertise</strong></p>
<ul>
<li>Neuroblastoma (adrenal tumors)</li>
<li>Wilms tumor (renal tumors)</li>
<li>Hepatoblastoma (liver tumors)</li>
<li>Germ cell tumors (including testicular and ovarian tumors)</li>
<li>Thyroid and other rare tumors</li>
<li>Experimental therapeutics</li>
<li>Cancer genetics and biomarkers</li>
</ul>
<p><strong>Board Certifications</strong></p>
<ul>
<li>Pediatrics</li>
<li>Pediatric Hematology/Oncology</li>
</ul>
<p><strong>Professional Education</strong></p>
<ul>
<li>M.D. &ndash; Stony Brook University, NY</li>
<li>Residency &ndash; Children&rsquo;s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Chief Residency &ndash; Children&rsquo;s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Fellowship &ndash; The Children&rsquo;s Hospital of Philadelphia, PA</li>
</ul>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

DR. Weiser's clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma, and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers.&nbsp;

Research Focus

Dr. Weiser&rsquo;s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser&rsquo;s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others.

Elsevier Profile

EMR ID

5755

Biography

<p>Daniel A. Weiser, MD, is a Medical Director of the Intra-abdominal Solid Tumor Program in the Pediatrics Hematology/Oncology department at Children&rsquo;s Hospital at Montefiore. He is also Associate Professor in the Pediatrics and Genetics departments at the Albert Einstein College of Medicine. His clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers. Dr. Weiser is actively involved in teaching and mentorship of trainees and takes great pride in his active participation in patient care.</p><p>Dr. Weiser received his Bachelor of Science in Neurobiology in 1995 at Haverford College, PA. In 2004, he received his Doctor of Medicine at Stony Brook University School of Medicine, NY. He is currently earning his Master of Science in Translational Research at the University of Pennsylvania. He began a residency in Pediatrics at the New York-Presbyterian, Columbia University in 2007. Dr. Weiser then completed a three-year fellowship in Pediatric Hematology/Oncology at The Children&rsquo;s Hospital of Philadelphia. </p><p>Dr. Weiser&rsquo;s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser&rsquo;s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others. His research has been published in many reviewed journals. </p><p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children&rsquo;s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), and the American Academy of Pediatrics (AAP). He has received many awards including the Brigid Leventhal Special Merit Award through ASCO, and he has been awarded a prestigious K12 from the NCI for the training of the next generation of physician-scientists in pediatric cancer.</p><p>He is board certified in Pediatric Hematology/Oncology and General Pediatrics.</p>

Is Open Scheduling

Off